H.C. Wainwright raised the firm’s price target on Exelixis (EXEL) to $47 from $40 and keeps a Buy rating on the shares. The company presented dose expansion results for zanzalitinib in first-line clear cell renal cell carcinoma, the most common type of kidney cancer in adults, the analyst tells investors in a research note. The firm says zanzalintinib plus Opdivo achieved a 63% confirmed overall response rate, with a median progression-free survival of 18.5 months. H.C. Wainwright increased its probability of approval for zanzalitinib in clear cell renal cell carcinoma to 60% from 50%.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EXEL:
- Exelixis price target raised to $46 from $45 at BofA
- Exelixis’s Zanza Pipeline: Balancing Risks and Opportunities Ahead of Key 2025 Readouts
- Exelixis Holds Annual Meeting, Elects New Directors
- Promising Clinical Data and Ongoing Trials Justify Buy Rating for Exelixis’s Zanzalintinib
- Exelixis’s Growth Potential Highlighted by Promising STELLAR-002 Trial Results and Buy Rating